--- title: "《盈警》海吉亞醫療預告全年淨利潤跌 66%-76%" description: "海吉亞醫療發盈警,預計 2025 年度淨利潤將下降 66%-76%,介乎 1.4 億至 2 億人民幣,主要受商譽減值影響。調整淨利潤預計為 4.5 億至 4.9 億人民幣,下降 19%-25%。全年收入預計介乎 40 億至 40.5 億人民幣,下降 9%-10%。收入和淨利潤下降主要受行業及宏觀經濟影響,以及新開業醫院的開辦費和折舊攤銷增加的影響。" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/274417161.md" published_at: "2026-02-01T09:59:15.000Z" --- # 《盈警》海吉亞醫療預告全年淨利潤跌 66%-76% > 海吉亞醫療發盈警,預計 2025 年度淨利潤將下降 66%-76%,介乎 1.4 億至 2 億人民幣,主要受商譽減值影響。調整淨利潤預計為 4.5 億至 4.9 億人民幣,下降 19%-25%。全年收入預計介乎 40 億至 40.5 億人民幣,下降 9%-10%。收入和淨利潤下降主要受行業及宏觀經濟影響,以及新開業醫院的開辦費和折舊攤銷增加的影響。 海吉亞醫療 (06078.HK) 發盈警,預計 2025 年度淨利潤介乎 1.4 億至 2 億人民幣,較上年度下降 66%-76%,主要受商譽減值影響;調整淨利潤 4.5 億至 4.9 億人民幣,下降 19%-25%;全年收入介乎 40 億至 40.5 億人民幣,下降 9%-10%。 年內,集團收入、淨利潤及經調整淨利潤下降主要由於行業及宏觀經濟影響,以及新開業醫院開辦費及折舊攤銷增加的影響。 ### Related Stocks - [06078.HK - 海吉亞醫療](https://longbridge.com/zh-HK/quote/06078.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Hygeia Healthcare Expects Upto 76% Lower 2025 Profit | Hygeia Healthcare Expects Upto 76% Lower 2025 Profit | [Link](https://longbridge.com/zh-HK/news/274456101.md) | | Hygeia Healthcare Issues Profit Warning for 2025 | Hygeia Healthcare Holdings Co. Ltd. has issued a profit warning for the year ending December 31, 2025, citing a prelimin | [Link](https://longbridge.com/zh-HK/news/274293772.md) | | Pop Mart’s Merodi Hong Kong debut highlights challenges of sustaining IP success | Pop Mart's recent launch of the Merodi character in Hong Kong has faced challenges, with low initial sales and limited c | [Link](https://longbridge.com/zh-HK/news/277174373.md) | | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/zh-HK/news/276886600.md) | | Anhui Conch Cement's controlling shareholder to increase holdings of company A-shares | Anhui Conch Cement's controlling shareholder to increase holdings of company A-shares | [Link](https://longbridge.com/zh-HK/news/276719000.md) | --- > **免責聲明**:本文內容僅供參考,不構成任何投資建議。